CN115210361B - 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物 - Google Patents

促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物 Download PDF

Info

Publication number
CN115210361B
CN115210361B CN202180017794.0A CN202180017794A CN115210361B CN 115210361 B CN115210361 B CN 115210361B CN 202180017794 A CN202180017794 A CN 202180017794A CN 115210361 B CN115210361 B CN 115210361B
Authority
CN
China
Prior art keywords
fibroblasts
epo
cells
kidney
positive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180017794.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN115210361A (zh
Inventor
岩宫贵纮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lymphatic Orgnex Co ltd
Original Assignee
Lymphatic Orgnex Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lymphatic Orgnex Co ltd filed Critical Lymphatic Orgnex Co ltd
Publication of CN115210361A publication Critical patent/CN115210361A/zh
Application granted granted Critical
Publication of CN115210361B publication Critical patent/CN115210361B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180017794.0A 2020-03-04 2021-03-04 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物 Active CN115210361B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020-036421 2020-03-04
JP2020036421 2020-03-04
PCT/JP2021/008325 WO2021177387A1 (ja) 2020-03-04 2021-03-04 エリスロポエチン産生能が亢進された線維芽細胞

Publications (2)

Publication Number Publication Date
CN115210361A CN115210361A (zh) 2022-10-18
CN115210361B true CN115210361B (zh) 2024-12-10

Family

ID=77614075

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180017794.0A Active CN115210361B (zh) 2020-03-04 2021-03-04 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物

Country Status (9)

Country Link
US (1) US20220411761A1 (https=)
EP (1) EP4116412A4 (https=)
JP (2) JP7229618B2 (https=)
KR (1) KR20220148184A (https=)
CN (1) CN115210361B (https=)
AU (1) AU2021230209B2 (https=)
CA (1) CA3174551A1 (https=)
IL (1) IL296125A (https=)
WO (1) WO2021177387A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023037868A1 (https=) * 2021-09-08 2023-03-16
WO2025135526A1 (ko) * 2023-12-19 2025-06-26 재단법인대구경북과학기술원 피부 또는 모발의 멜라닌 색소 조절용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003174897A (ja) * 1991-11-05 2003-06-24 Transkaryotic Therapies Inc 相同組換えによる脊椎動物細胞等のトランスフェクション
CN109890398A (zh) * 2017-02-24 2019-06-14 玛土撤拉有限公司 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6946246B1 (en) * 1997-04-08 2005-09-20 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Production of functional proteins: balance of shear stress and gravity
JP2004516820A (ja) 2000-08-25 2004-06-10 キュラジェン コーポレイション 新規タンパク質およびそれらのタンパク質をコードする核酸
JP5404951B2 (ja) 2008-04-22 2014-02-05 キヤノン株式会社 制御装置
KR101735125B1 (ko) 2008-11-12 2017-05-15 리젠메드 (케이만) 엘티디. 분리된 신장 세포 및 이의 용도
CN103154236B (zh) 2010-05-12 2016-08-31 再生医学Tx有限责任公司 生物活性肾细胞
CA2954743C (en) 2014-07-11 2022-03-15 Metcela Inc. Cardiac cell culture material
CA3110831A1 (en) * 2018-08-29 2020-03-05 Metcela Inc. Method for producing fibroblast, and g-csf-positive fibroblast mass

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003174897A (ja) * 1991-11-05 2003-06-24 Transkaryotic Therapies Inc 相同組換えによる脊椎動物細胞等のトランスフェクション
CN109890398A (zh) * 2017-02-24 2019-06-14 玛土撤拉有限公司 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Implications of the Upregulation of ICAM-1/VCAM-1 Expression of Corneal Fibroblasts on the Pathogenesis of Allergic Keratopathy;Naoko Okada et al.;Investigative Ophthalmology & Visual Science;46卷(12期);第 4512页第 1栏摘要部分、Figure 2 *

Also Published As

Publication number Publication date
JPWO2021177387A1 (https=) 2021-09-10
JP2023053044A (ja) 2023-04-12
EP4116412A4 (en) 2024-04-03
AU2021230209B2 (en) 2025-01-30
JP7229618B2 (ja) 2023-02-28
EP4116412A1 (en) 2023-01-11
KR20220148184A (ko) 2022-11-04
IL296125A (en) 2022-11-01
CN115210361A (zh) 2022-10-18
AU2021230209A1 (en) 2022-09-29
WO2021177387A1 (ja) 2021-09-10
US20220411761A1 (en) 2022-12-29
CA3174551A1 (en) 2021-09-10

Similar Documents

Publication Publication Date Title
JP6883904B2 (ja) 線維芽細胞の製造方法及びｇ−ｃｓｆ陽性線維芽細胞集団
US20120148544A1 (en) Treatment of Diseases and Disorders Using Self-Renewing Colony Forming Cells Cultured and Expanded In Vitro
CN110898078B (zh) 一种间充质干细胞分泌因子的制备及应用
TW201130977A (en) Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood
CN105769910B (zh) 一种人羊膜间充质干细胞的应用
CN115210361B (zh) 促红细胞生成素产生能力增强的成纤维细胞、制造方法以及医药组合物
Benny et al. Comparative effects of bone marrow-derived versus umbilical cord tissue mesenchymal stem cells in an experimental model of bronchopulmonary dysplasia
CN107073041A (zh) 糖尿病性皮肤溃疡治疗的多功能性干细胞
EP1857542A1 (en) Method for in vitro amplification of adult stem cells
WO2004100972A1 (ja) 組織破壊を伴う疾患の予防及び／または治療剤
JP6766082B2 (ja) 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途
CN114901806B (zh) 细胞群以及其取得方法
JP2018530992A6 (ja) 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途
US20240316113A1 (en) Fibroblast-containing pharmaceutical composition for treating kidney disease
KR20100089927A (ko) 세포 스페로이드 형태의 이식용 성체 줄기세포 집합체 및 그 제조방법
CN103977395A (zh) 生长因子制剂及其生产方法
CN117120063A (zh) 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物
KR100812544B1 (ko) 제대혈 유래 다분화능 줄기세포 및 이를 함유하는 허혈성괴사질환 치료용 세포치료제
CN101837014A (zh) 用于治疗慢性肾脏疾病之医药组合物
RU2800644C2 (ru) Способ получения фибробластов и г-ксф-положительная фибробластная масса
RU2742034C2 (ru) Бесклеточные терапевтические средства для регенеративной медицины и способы их получения
RATAJCZAK Primed stem cells and platelet concentrates: two biological strategies to enhance angiogenesis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20241024

Address after: London

Applicant after: Lymphatic Orgnex Co.,Ltd.

Country or region after: Britain

Address before: Yamagata Prefecture, Japan

Applicant before: METCELA Inc.

Country or region before: Japan

GR01 Patent grant
GR01 Patent grant